AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
Overview
Investors seeking reliable dividends often look to the healthcare sector, but choosing between AbbVie Inc (NYSE:ABBV) and Pfizer Inc (NYSE:PFE) requires a close look at their post-pandemic growth strategies and pipelines.
AbbVie focuses on high-margin specialty medicines in immunology and oncology, while Pfizer operates a broader portfolio spanning vaccines, primary care, and specialized cancer treatments. Both companies are navigating significant patent expirations, making their current research pipelines and acquisition strategies the primary drivers for long-term shareholder value in 2026.
Details
AbbVie focuses on discovering and delivering innovative medicines for complex health issues through a global workforce of roughly 57,000 employees. Its U.S. pharmaceutical sales are heavily concentrated among three major wholesale distributors: McKesson Corporation (NYSE:MCK), Cardinal Health (NYSE:CAH), and Cencora (NYSE:COR). Customer concentration like this adds a layer of risk to the business because these three firms account for almost all domestic product sales.
Source
Originally published at www.fool.com.
